| Literature DB >> 31116259 |
Domenico Madonna1,2, Giuseppe Delvecchio1, Jair C Soares3, Paolo Brambilla2,3.
Abstract
OBJECTIVES: Brain imaging studies carried out in patients suffering from generalized anxiety disorder (GAD) have contributed to better characterize the pathophysiological mechanisms underlying this disorder. The present study reviews the available functional and structural brain imaging evidence on GAD, and suggests further strategies for investigations in this field.Entities:
Mesh:
Year: 2019 PMID: 31116259 PMCID: PMC6804309 DOI: 10.1590/1516-4446-2018-0108
Source DB: PubMed Journal: Braz J Psychiatry ISSN: 1516-4446 Impact factor: 2.697
Figure 1Study selection flow chart.DTI = diffusion tensor imaging; DWI = diffusion weighted imaging; GAD = generalized anxiety disorder; MRI = magnetic resonance imaging.
Structural findings
| Study | Sample n, mean age (years) ± SD | Sex (F/M) | Comorbidity (n) | Drugs | Method | Main findings |
|---|---|---|---|---|---|---|
| De Bellis | GAD = 12, 12.7±2.4 | GAD=5/7 | DDNOS = 3 | Twelve drug-naïve participants | 1.5 T MRI | Larger amygdala in GAD patients vs. HC: right>left |
| De Bellis | GAD = 13, 12.5±2.5 | GAD=5/8 | DDNOS = 3 | Twelve drug-naïve participants | 1.5 T MRI | Larger total GM and WM STG in GAD patients vs. HC |
| Milham | GAD+SP+SAD=17 (GAD = 13; SP = 9; SAD = 3), 12.9±2.3HC = 34, 14.4±2.2 | GAD+SP+ | MDD = 4 | Two participants with previous AD exposure | 3 T MRI | GM volume reduction in left amygdala in patients with anxiety disorders vs. HC |
| Mohlman | GAD = 15, 67.39±5.42 | GAD = 7/8 | Dysthymia = 3 | No current psychotropic drug use (1 year before the study) | 1.5 T MRI | No difference in mOFC, DLPFC, and amygdala volumes |
| Brambilla | GAD = 12 | GAD = 8/4 | No psychiatric comorbidity | Seven subjects exposed to AD and six to | 1.5 T DWI-MRI | Greater ADC measures in the right splenium of the corpus callosum and parietal cortex in GAD patients vs. HC |
| Schienle | GAD = 16, 22.9±4.1 | GAD = 16/0 | No psychiatric comorbidity | No current psychotropic drug use | 3 T MRI | Larger GM volumes of amygdala and DMPFC in GAD patients vs. HC |
| Zhang | GAD = 20, 30.80±8.58 | GAD = 8/12 | No psychiatric comorbidity | No current psychotropic drug use | 1.5 T DTI-MRI | Increased FA in right postcentral gyrus in GAD vs. HC; reduced FA in right ACC in PTSD patients vs. GAD patients. |
| Tromp | GAD = 49, 27.10±10.61 | GAD = 30/19 | MDD = 20 | No current psychotropic drug use | 3 T DTI-MRI | Lower FA in UF in GAD patients vs. HC |
| Terlevic | GAD = 12, 42.10±11.4 | GAD = 8/4 | No psychiatric comorbidity | Seven subjects from the GAD group and eight subjects from the PD group exposed to AD | 1.5 T MRI | Decreased hypothalamus volume bilaterally in GAD patients, but not in PD patients, vs. HC |
| Zhang | GAD = 16, 30.38±8.35 | GAD = 7/9 | No psychiatric comorbidity | No current psychotropic drug use | 1.5 T DTI-MRI | Increased FA in right amygdala in GAD patients vs. HC |
| Liao | GAD-CM = 14, 17±0.20 | GAD-CM = 7/7 | No other current MDD or other anxiety disorder | No current psychotropic drug use | 3 T MRI | Larger right putamen GM in GAD patients vs. HC |
| Strawn | GAD = 15, 13±2 | GAD = 8/7 | ADHD = 6 | No current psychotropic drugs | 4 T MRI | Increased GM in right PCu and precentral gyrus in GAD patients vs. HC |
| Liao | GAD = 25, 16.96±0.68 | GAD = 13/12 | No other current psychiatric disorders | No current psychotropic drugs | 3 T DTI-MRI | Reduced FA in bilateral UF, inferior fronto-occipital fasciculus, inferior longitudinal fasciculus and corona radiata in GAD patients vs. HC |
| Liao | GAD-M = 13, 16.77±0.73 | GAD = 13/13 | No other current psychiatric disorders | No current psychotropic drug use | 3 T MRI | Larger right putamen GM in GAD patients vs. HC |
| Moon | GAD = 22, 37.0±10.7 | GAD = 9/13 | No other current psychiatric disorders | No current psychotropic drug use | 3 T MRI | Reduced GM in hippocampus, midbrain, thalamus, insula, and STG in GAD patients vs. HC |
| Cha | GAD = 32, 22.3±5.14 | GAD = 32/0 | MDD = 17 | No current psychotropic drug use | 3 T MRI, DTI and fMRI | GAD patients with thicker VMPFC display a more discriminate VMPFC reactivity during the fear task vs. HC |
| Hilbert | GAD = 19, 33.47±8.9 | GAD = 16/3 | 16 of the GAD subjects had at least one comorbidity | No current psychotropic drug use | 3 T MRI | Higher GM volumes in basal ganglia structures and lower in the superior temporal pole in GAD patients vs. HC |
| Moon & Jeong | GAD = 22, 37±10.7 | GAD = 9/13 | All patients had primary GAD with mild depression | Eighteen patients had prescriptions for multiple psychiatric medications, including anxiolytics (buspirone [n=8]; alprazolam [n=3]; zolpidem [n=1]; tofisopam [n=2]; lorazepam [n=1]) and/or antidepressants (escitalopram [n=10]; bupropion [n=1]; fluvoxamine [n=2]; duloxetine [n=2]; paroxetine [n=3]). Four patients were taking one psychotropic medication. | 3 T MRI | Reduced WM volumes in DLPFC and anterior limb of internal capsule in GAD patients vs. HC |
| Strawn | GAD+SP+SAD = 38, 14.4±3.3 | GAD+SP+ | No other current psychiatric disorders | No current psychotropic drug use | 3 T MRI | Larger GM volumes in the dorsal ACC in GAD patients vs. HC |
| Moon | GAD = 17, 37.4±11.3 | GAD = 6/11 | All patients had primary GAD with mild depression | Eleven patients had prescriptions for multiple psychiatric medications, including anxiolytics (buspirone [n=5]; alprazolam [n=2]; lorazepam [n=1]; tofisopam [n=2]) and/or antidepressants (escitalopram [n=9]; bupropion [n=1]; fluvoxamine [n=1]; duloxetine [n=2]; mirtazapine [n=1]; paroxetine [n=3]). | 3 T MRI and fMRI | Significant reduction in GM volumes especially in the hippocampus, midbrain, thalamus, insula, and STG in GAD patients vs. HC |
| Moon & Jeong | GAD = 13, 37.8±7.6 | GAD = 6/7 | All patients had primary GAD with mild depression | Eighteen patients had prescriptions for multiple psychiatric medications, including anxiolytics (buspirone [n=5]; alprazolam [n=3]; zolpidem [n=1]; tofisopam [n=2]) and/or antidepressants (escitalopram [n=9]; bupropion [n=1]; fluvoxamine [n=1]; duloxetine [n=1]). Six patients each were taking one psychotropic medication. | 3 T MRI | Reduced WM volumes in the midbrain, precentral gyrus, DLPFC and anterior limb of the internal capsule in GAD patients vs. HC |
| Moon & Jeong | GAD = 17, 38.1±10.4 | GAD = 9/8 | All patients had primary GAD with mild depression | Eleven patients had prescriptions for multiple psychiatric medications, including anxiolytics (buspirone [n=4]; alprazolam [n=1]; lorazepam [n=2]; tofisopam [n=2]) and/or antidepressants (escitalopram [n=9]; bupropion [n=1]; fluvoxamine [n=2]; duloxetine [n=1]; mirtazapine [n=1]; paroxetine [n=3]). Six patients received one psychiatric medication each. | 3 T MRI and fMRI | Reduction of WM volumes in the DLPFC, anterior limb of the internal capsule, and midbrain in GAD patients vs. HC |
| Cha | GAD and GAD/MDD = 32 | GAD and GAD/ | MDD = 17 | No current psychotropic drug use | 3 T MRI, DWI and fMRI (multimodal MRI) | GAD patients showed significantly decreased cue repetition effects in the left anterior hippocampus |
| Wang | GAD = 28, 32.93±4.13 | GAD = 14/14 | No other current psychiatric disorders | No current psychotropic drug use | 3 T DTI-MRI | Decreased FA of WM in bilateral UF, corpus callosum, cingulate gyrus, bilateral anterior thalamic radiation and corona radiate, right anterior limb of internal capsule, bilateral inferior frontal-occipital fasciculus, bilateral superior, and inferior longitudinal fasciculus vs. GAD patients vs HC |
| Makovac | GAD = 19, 30.0±6.9 | GAD = 16/3 | No other current psychiatric disorders | Two GAD participants were included who used long-term medications (one citalopram, one pregabalin) at the time of the study. All other patients and controls were medication free. | 1.5 T MRI | Before induction: lower GM volume within SMG, precentral, and postcentral bilaterally in GAD patients vs. HC |
| Molent | GAD = 31, 43.8±14.9 | GAD = 20/11 | MDD = 1Specific phobia = 2 (at the time of MRI) | Eighteen patients had prescriptions for multiple psychiatric medications, including antidepressants (escitalopram [n=4]; paroxetine [n=3]; sertraline [n=2]; mirtazapine [n=2]; citalopram [n=2]; venlafaxine [n=1]; duloxetine [n=1]) and antipsychotic (amisulpride [n=1]). | 3 T MRI | Reduced cortical thickness in right caudal middle frontal gyrus in GAD patients vs. HC |
ACC = anterior cingulate cortex; AD = antidepressive medication; ADC = apparent diffusion coefficient; ADHD = attention deficit and hyperactivity disorder; BDZ = benzodiazepines; CM = childhood maltreatment; DDNOS = depressive disorder not otherwise specified; DLPFC = dorsolateral prefrontal cortex; DMPFC = dorsomedial prefrontal cortex; DTI-MRI = diffusion tensor imaging; DWI-MRI = diffusion weighted imaging; F = female; FA = fractional anisotropy; FuG = fusiform gyrus; GAD = generalized anxiety disorder; GM = gray matter; HC = healthy control; M = male; MDD = major depressive disorder; mOFC = medial orbitofrontal cortex; MRI = magnetic resonance imaging; n = patients; PCu = precuneus; PD = panic disorder; PFC = prefrontal cortex; PTSD = posttraumatic stress disorder; SAD = separation anxiety disorder; SD = standard deviation; SMG = supramarginal gyrus; SP = social phobia; STG = superior temporal gyrus; UF = uncinate fasciculus; VLPFC = ventrolateral prefrontal cortex; VMPFC = ventromedial prefrontal cortex; WCM = without childhood maltreatment; WM = white matter.
In this study GAD, SP, and SAD were considered as a whole group.
Functional MRI studies
| Study | Sample n, mean age (years) ± SD | Sex (F/M) | Comorbidity (n) | Drugs | Method | Main findings |
|---|---|---|---|---|---|---|
| Thomas | GAD + PD = 12, 12.8±2.1 | GAD + PD = 5/7 | SP = 1 | No current psychotropic drug use | 1.5 T fMRI Task = facial emotion processing task | Greater amygdala response to fearful faces in patients with anxiety vs. HC |
| Hoehn-Saric | GAD = 6, 36.0 | GAD = 3/3 | No psychiatric comorbidity | No current psychotropic drug use | 1.5 T fMRI Task = verbal descriptions of a personal worry or a neutral statement Seven weeks of therapy with citalopram | Post-treatment: reduced activation in prefrontal regions, striatum, insula, and paralimbic regions during processing of worry sentences |
| Monk | GAD = 18, 12.28±2.0 | GAD = 8/10 | MDD = 9 | No current psychotropic drug use | 3 T fMRI Task = facial emotion processing task | Greater VLPFC response to angry faces in GAD patients vs. HC |
| McClure | GAD = 15, 11.67±1.97 | GAD = 7/8 | SAD = 5 | Unknown | 3 T fMRI Task = facial emotion processing task | Greater response to fearful faces in amygdala, vPFC, ACC in GAD patients vs. HC |
| Krain | GAD + SP = 16, 15.2±1.3 | GAD + | SP = 10 | Unknown | 3 T fMRI Task = decision-making task | No brain hyperactivation in patients with anxiety vs. HC High level of intolerance to uncertainty associated with higher activation of amygdala, rostral, and subgenual ACC in patients with anxiety vs. HC |
| Monk | GAD = 17, 13.12±2.09 | GAD = 6/11 | MDD = number not known | No current psychotropic drug use | 3 T fMRI Task = facial emotion processing task | Greater response in amygdala while viewing masked angry faces in GAD patients vs. HC. Amygdala and VLPFC showed strong negative coupling specifically to masked angry faces in GAD patients vs. HC |
| Blair | GAD = 17, 35.0±10.6 | GAD = 11/6 | SP = 7 MDD = 1 | No current psychotropic drug use | 1.5 T fMRI Task = facial emotion processing task | Greater response in angry expression in right middle frontal gyrus in GAD patients vs. HC |
| Whalen | GAD = 15, 27.0±7.0 | GAD = 12/3 | No other current disorder | No current psychotropic drug use | 3 T fMRI Task = facial emotion processing task eight weeks of therapy with venlafaxine | No different amygdala and rACC reactivity to threatening stimuli in GAD patients vs. HC Individual pre-treatment responsivity (greater rACC and lesser amygdala) predicted by treatment response in GAD patients vs. HC |
| Etkin | GAD = 16, 30.6±1.7 | GAD = 14/2 | MDD = 4 SP = 5 PD = 2 Dysthymia = 2 OCD = 1 | Four subjects exposed to AD at the moment of the study | 3 T rs-fMRI and MRI | BLA and CMA disconnectivity in GAD patients vs. HC with: DLPFC and posterior parietal cortex (increased);insula and cingulate (decreased); larger amygdalar GM (in particular right CMA) |
| Nitschke | GAD = 14, 33.7±10.2 | GAD = 12/2 | No other current disorder Past MDD = 10 | No current psychotropic drug use |
3 T fMRI Tasks = warning cue that preceded aversive pictures and a second cue that preceded neutral pictures | Greater bilateral dorsal amygdala activation during anticipation of both aversive and neutral pictures in GAD patients (aversive>neutral) vs. HCGreater pre-treatment pgACC activation during anticipation of both aversive and neutral trials predicted better treatment response in GAD patients vs. HC |
| Paulesu | GAD = 8, 24.1±6.6 | GAD = 5/3 | Not known | No current psychotropic drug use | 1.5 T fMRI Task = mood induction paradigm | Hyperactivation of ACC and DMPFC after worry stimulation in both GAD patients and HC Persistent activation after stimulation in GAD patients only |
| Etkin[81] | GAD = 17, 31.5±9.9 | GAD = 11/6 | Dysthymia = 2 | Five subjects had never received AD No psychotropic drugs within at least 48 h | 3 T fMRI Task = emotional conflict task | Failure to activate pgACC during emotional conflict in GAD patients vs. HC |
| Maslowsky | GAD-CBT = 7, 13.4±1.7 | GAD-CBT = 4/3 | SP = 6 | No current psychotropic drug use |
3 T fMRI Task = facial emotion processing task | Increased right VLPFC activation after treatment (CBT and SSRI) in GAD patients vs. HC |
| Guyer | GAD = 18, 12.91±2.67 | GAD = 10/8 | MDD = 5 | No current psychotropic drug use | 3 T fMRI Task = monetary incentive delay task | Hyperactivation of putamen in response to valence in GAD patients vs. SP patients and HC No caudate increased activation as incentive increased in GAD patients and HC vs. SP patients |
| Etkin & Schatzberg | GAD = 18, 31.3±9.5 | GAD = 11/7 | Dysthymia = 2 | No current psychotropic drug use | 3 T fMRI Task = emotional conflict task | Hyperactivation of ventral ACC and amygdala in GAD and MDD patients vs. HC |
| Palm | GAD = 15, 34±13 | n=15/0 | Past MDD = 1 Past alcohol dependence = 1 Other anxiety disorder (PD, SP, specific phobia) = 10 | Three subjects exposed to AD at the moment of the study | 1.5 T fMRI Task = facial emotion processing task | Hypoactivation of VLPFC, MPFC, and ACC across emotional expression, especially happy faces in GAD patients vs. HC No amygdala dysregulation in GAD patients vs. HC |
| Andreescu | GAD = 7, 63.3±3.9 | GAD = 5/2 | SP = 3 | No current psychotropic drug use | fMRI-pulse arterial spin labelling perfusion at rest and during task Task = worry modulation task | Resting-state: increased activity during worry induction in the associative temporo-occipital areas, but not in the insulaor the amygdala in GAD patients vs. HC Worry suppression: Increased activity in dorsal ACC, but not in PFC in GAD patients vs. HC |
| Blair | - EER GAD = 17, 36.1±11.75 | - EER | No other current psychiatric disorders | No current psychotropic drug use | 1.5 T fMRI Task1 = EER Task2 = TAC | HC showed significantly increased recruitment during emotion regulation, relative to emotion- picture viewing. GAD, SP, and SP/GAD patients showed no such increases. Decreased amygdala activation to negative stimuli only for GAD patients vs. HC |
| Strawn | GAD = 10, 14±2.2 | GAD = 6/4 | No other current psychiatric disorders | No current psychotropic drug use | 4 T fMRI Task = continuous performance task with emotional and neutral distractors | Increased activation in left medial PFC and right VLPFC in response to emotional images in GAD patients vs. HC Decreased connectivity between VLPFC and bilateral medial PFC in GAD patients vs. HC Decreased correlation between right amygdala and PCC in GAD patients vs. HC Increased correlation between left amygdala and ipsilateral PCu in GAD patients vs. HC |
| Yassa | GAD = 15, 34.7±9.51 | GAD = 12/3 | No other current psychiatric disorders | No current psychotropic drug use | 3 T fMRI Task = gambling game with non-contingent monetary loss | Decreased amygdala and BNST activity in GAD patients vs. HC |
| Roy | GAD = 15, 14.9±1.7 | GAD = 10/5 | SP = 5 | No current psychotropic drugs | 3 T rs-fMRI | Disruption in amygdala connectivity with medial PFC, insula, and cerebellum in GAD patients vs. HC Positive correlation between anxiety severity scores and connectivity between amygdala, insula, and STG in GAD patients vs. HC |
| Chen & Etkin | GAD = 39, 32.4±1.5 | GAD = 27/12 | MDD = 23 | No current psychotropic drug use | 3 T fMRI resting-state + fMRI Task 1 = flashing checker board Task 2 = facial emotion processing task | Disturbed posterior hippocampus and default-mode network connectivity during resting-state and task execution in PTSD, but not in GAD patients or HC |
| Hölzel | GAD = 26, 37.9±12.2 | GAD = 14/12 | MDD = 4 | Four subjects exposed to AD at the moment of the study |
1.5 T fMRI Task = facial emotion processing task | Pre-treatment: higher amygdala activation in response to neutral, but not angry faces in GAD patients vs. HC Post-treatment: reduction of amygdala activation in response to neutral faces in GAD patients vs. HC Higher VLPFC activation after MBSR vs. SME in GAD patients vs. HC Increased connectivity between amygdala and PFC after MBSR in GAD patients vs. HC Correlation between activation/ connectivity and symptoms in GAD patients vs. HC |
| Ball | GAD = 23, 35±11 | GAD = 17/5 | GAD group: | No current psychotropic drug use | 3 T fMRI Task: negative emotion processing task | PFC hypoactivation in GAD and PD patients vs. HC HC demonstrated greater activation during both reappraisal and maintenance of negative emotions then GAD patients in DMPFC, bilateral dorsolateral and ventrolateral PFC, and dorsal ACC |
| Andreescu | GAD-old = 15, 67.4±6.52 | GAD-old = 11/4 | PD = 4 | No current psychotropic drug use | 3 T rs-fMRI | Greater anxiety effect on connectivity between PCC and MPFC in older GAD patients vs. young subjects Positive correlation between duration of illness and greater connectivity between PCC and insula |
| Andreescu | Elderly GAD = 28, 64±6.75 | GAD = 17/11 | SP = 1 | No current psychotropic drug use | 3 T rs-fMRI | Higher connectivity in GAD patients in the DLPFC and several prefrontal regions during worry reappraisal, after 12 weeks of treatment vs. HC |
| Fonzo | GAD = 21, 34.29±11.27 | GAD = 16/5 | Anxiety or mood disorder comorbidity permitted for GAD participants | No current psychotropic drug use | 3 T fMRI Task: facial emotion processing task | Pre-treatment: GAD patients showed blunted responses in amygdala, insula, and ACC to the happy faces and greater amygdalo-insular connectivity vs. HC Post-treatment: CBT attenuated amygdalar and subgenual ACC activation by fear/angry faces and heightened insular responses to the happy face comparison condition, but no apparent effects on connectivity in GAD patients vs. HC |
| Cha | GAD = 32, 22.3±5.14 | GAD = 32/0 | MDD = 17 | No current psychotropic drug use | 3 T fMRI Task: fear generalization task | Higher and less discriminating VTA reactivity to generalized stimuli in GAD patients vs. HC Increased connectivity in VTA-nucleus accumbens in GAD patients vs. HC |
| Cha | GAD = 32, 22.3±5.14 | GAD = 32/0 | MDD = 17 | No current psychotropic drug use | 3 T fMRI, DTI, and MRI Task: fear generalization task | GAD patients with thicker VMPFC display more discriminate VMPFC reactivity during the fear task vs. HC Increased connectivity VMPFC in GAD vs. HC |
| Brown | GAD = 30 | BDZ = 9/10 | No other current psychiatric disorders | No current psychotropic drug use | 3 T fMRI Task: EFMT and affective STIMEX were performed at baseline, 1 hour after initial drug administration and 28 days later | Activation of amygdala during EFMT in GAD patients vs. HC Decreased activation of amygdala after treatment with BDZ in GAD patients vs. HC Significant treatment differences in brain activity during the STIMEX on day 28 in frontal lobe, caudate nucleus, middle temporal gyrus, secondary visual cortex, and SMG in GAD patients vs. HC |
| Liu | GAD = 26, 15.54±1.53 | GAD = 16/10 | No other current psychiatric disorders | No current psychotropic drug use | 3 T rs-fMRI | Decreased functional connectivity between left amygdala and left DLPFC in GAD patients vs. HC Increased functional connectivity between right amygdala and right posterior and anterior lobes of the cerebellum, insula, STG, and putamen in GAD patients vs. HC |
| Makovac | GAD = 19, 29.58±6.93 | GAD = 17/2 | No other current psychiatric disorders | No current psychotropic drug use | 1.5 T fMRI resting-state + task Task = visuomotor tracking task | Before induction: lower connectivity between right amygdala and right SFG, right paracingulate ACC, and right SMG and decreased connectivity between VLPFC and amygdala in GAD patients vs. HC After induction: connectivity increased in GAD patients but decreased in HC |
| Moon | GAD = 17, 37.4±11.3 | GAD = 6/11 | All patients had primary GAD with mild depression | Eleven patients had prescriptions for multiple psychiatric medications, including anxiolytics (buspirone [n=5/; alprazolam [n=2]; lorazepam [n=1]; tofisopam [n=2]) and/or antidepressants (escitalopram [n=9]; bupropion [n=1], fluvoxamine [n=1], duloxetine [n=2], mirtazapine [n=1], paroxetine [n=3]). | 3 T MRI + fMRI Task: explicit verbal memory tasks with emotionally neutral and anxiety-inducing words | In response to neutral words, GAD patients showed lower activity in hippocampus, middle cingulate gyrus, putamen, and head of caudate nucleus vs. HC In response to anxiety-inducing words, GAD patients showed higher activities in VLPFC and precentral gyrus vs. HC Significant reduction in GM volumes, especially in the hippocampus midbrain, thalamus, insula, and STG in GAD patients vs. HC |
| Park | GAD = 15, 36.4±11.2 | GAD = 7/8 | No other current psychiatric disorders | Fourteen patients had prescriptions for multiple psychiatric medications, including antidepressants (escitalopram [n=8]; paroxetine [n=2], bupropion [n=1]; fluvoxamine [n=1]; duloxetine [n=1]; mirtazapine [n=1]) and/or anxiolytics (buspirone [n=6], alprazolam [n=5], zolpidem [n=1]). | 3 T fMRI Task: explicit verbal memory tasks with emotionally neutral and anxiety-inducing words | Increased activation with anxiety-provoking pictures vs. neutral pictures in: VLPFC, middle temporal gyrus, inferior occipital gyrus, inferior temporal gyrus, middle occipital gyrus, hippocampus, PHG, FuG, DLPFC, STG amygdala, cerebellar cortex, LiG, PCu, SPG |
| Buff | GAD = 20, 28.10±8.73 | GAD = 16/4 | No other current psychiatric disorders | Six to seven patients per group took long-term medication (antidepressive medication, one GAD patient used Pregabalin) and had been stabilized on such medication for at least 4 weeks prior to study participation. | 3 T fMRI Task: explicit verbal memory tasks with emotionally neutral and anxiety-inducing words | Elevated activity with threat vs. neutral in cingulate cortex, dorsal anterior insula/frontal operculum, and posterior DLPFC in GAD patients vs. other groups Increased functional connectivity between posterior DLPFC and VLPFC, between cingulate cortex and amygdala, between cingulate cortex and anterior insula in GAD patients vs. other groups |
| Cui | GAD = 21, 39.95±12.24 | GAD = 7/13 | No other current psychiatric disorders | No current psychotropic drug use | 3 T rs-fMRI | Increased functional connectivity between hippocampus/parahippocampus and FuG in GAD patients vs. PD patients and HC |
| Kujawa | GAD+SAD+GSAD = 4 17-19 years | Not specified | Participants with secondary comorbidity were included: 70.7% of the sample had current diagnoses of GAD, 58.5% GSAD, and 17.1% SAD, 7.3% had comorbid PD, 9.8% OCD, 24.4% specific phobia, 2.4% PTSD, 2.4% depression, and 12.2% ADHD | No current psychotropic drug use | 3 T fMRI Task: flanker task to elicit error-related negativity Twelve weeks of SSRI or 18 sessions (max) of CBT | Greater activation of inferior and SFG, including DLPFC and VLPFC, precentral/postcentral gyri during processing of threating faces predicted greater response to CBT and SSRI treatment |
| Makovac | GAD = 16, 29.62±7.51 | GAD = 14/2 | No other current psychiatric disorders | Two GAD patients using long-term medications (one citalopram, one pregabalin) at both sessions of the study. All other patients and controls were medication free. | 1.5 T fMRI resting-state + task Task = visuomotor tracking task | After induction: reduction in connectivity between right amygdala and VMPFC in GAD patients vs. HC At follow-up: enhanced coupling between left amygdala and VTA Amplified physiological response to induction predicted increased connectivity between right amygdala and thalamus in GAD patients vs. HC |
| Wang | GAD = 28, 32.93±4.13 | GAD = 14/14 | No other current psychiatric disorders | No current psychotropic drug use | 3 T rs-fMRI |
Higher amplitude of low frequency fluctuations in bilateral DMPFC and DLPFC, as well as left PCu/PCC in GAD patients vs. HC |
| Moon & Jeong | GAD = 17, 38.1±10.4 | GAD = 9/8 | All patients had primary GAD with mild depression | Eleven patients had prescriptions for multiple psychiatric medications, including anxiolytics (buspirone [n=4]; alprazolam [n=1]; lorazepam [n=2]; tofisopam [n=2]) and/or antidepressants (escitalopram [n=9]; bupropion [n=1]; fluvoxamine [n=2]; duloxetine [n=1]; mirtazapine [n=1]; paroxetine [n=3]), and six patients used one psy-qj;chiatric medication each. | 3 T MRI and fMRI Task: verbal working memory task with emotionally neutral and anxiety-inducing words |
Lower activity in FuG, SPG, PCu, SOG, LiG, Cun, CaC, PHG, and Cb in GAD patients vs. HC |
| Moon | GAD = 14, 36.6±8.8 | GAD = 6/8 | All patients had primary GAD with mild depression | Eleven patients had prescriptions for multiple psychiatric medications including anxiolytics (buspirone [n=7]; alprazolam [n=3]; tofisopam [n=1]) and/or antidepressants (escitalopram [n=10]; bupropion [n=3]; fluvoxamine [n=2]; duloxetine [n=1]) and three patients used a single psychiatric medication. | 3 T fMRI Task: working memory task with emotion- inducing distractors | In response to emotional distractors higher activity in the hippocampus and lower activities in the SOG, SPG, DLPFC, and precentral gyrus was found in GAD patients vs. HC |
| Cha | GAD + GAD/MDD = 32 | GAD = 32/0 | MDD = 17 | No current psychotropic drug use | 3 T MRI, DTI and fMRI (multimodal MRI) Task: threat-associative learning task | Decreased activity in left anterior hippocampus to cue repetition in GAD patients (with or without comorbidity with MDD) during a threat-associative learning task |
| Burkhouse | GAD + GSAD = 37 (7-19 age) | GAD + GSAD = 22/15 | 10.8% SAD; 10.8% PD; Specific phobia 18.9%, MDD 5.4%, ADHD 16.2% | No current psychotropic drug use | 3 T fMRI Task: emotional faces shifting attention tasksTen weeks (minimum) of SSRI or CBT | Reduced activation in SFG, ACC, and DMPFC during implicit processing of emotional faces after treatment (both CBT and SSRI) |
| Meeten | GAD = 19, 29.58±6.93 | GAD = 17/2 | Patients had primary GAD with mild depression | Two GAD patients with long-term medication (one citalopram, one pregabalin) | 3 T rs-fMRI | Increased connectivity between right amygdala and brainstream in GAD patients vs. HC |
| Moon | GAD = 15, 37.6±11.9 | GAD = 5/10 | All patients had primary GAD with mild depression | Eight patients had prescriptions for multiple psychiatric medications, including anxiolytics (buspirone [n=2]; alprazolam [n=2]; lorazepam [n=1]; and tofisopam [n=1]) and/or antidepressants (escitalopram [n=7]; bupropion [n=1]; fluvoxamine [n=1]; duloxetine [n=1]; mirtazapine [n=1]; and paroxetine [n=3]). Seven patients were taking one psychotropic medication. | 3 T fMRI Task: explicit memory task with neutral and anxiety-inducing words |
Decreased activity in putamen, head of the caudate nucleus, hippocampus, and middle cingulate gyrus during the memory tasks with the neutral and anxiety-inducing words in GAD patients vs. HC |
| Li | GAD = 21, 39.90±12.24 | GAD = 7/13 | No other current psychiatric disorders | No current psychotropic drug use | 3 T rs-fMRI | Increased functional connectivity between left amygdala and temporal pole in GAD patients vs. HC In both eyes-open and eyes-closed conditions, the brain regions showed altered FC with amygdala/DLPFC in GAD patients vs. HC |
| Karim | GAD = 17, 64±6 | GAD = 10/7 | Patients with other anxiety disorders were included if GAD was the principal diagnosis | No current psychotropic drug use | 3 T fMRI Task: facial emotion processing task |
Positive association between the faces > shapes and global anxiety in PHG, precuneus, and superior occipital gyrus |
| Diwadkar | GAD = 10, 41.65±12.47 | GAD = 6/4 | No other current psychiatric disorders | Seven patients receiving antidepressants at the time of MRI (three on venlafaxine, one on amitriptyline, three on SSRIs: sertraline, citalopram, and escitalopram). Five patients were taking benzodiazepines, two patients were medication free. | 3 T fMRI Task: explicit verbal memory tasks with emotionally neutral and anxiety-inducing words | Hypoactivation in dorsal ACC, VLPFC, and cerebellum, more pronounced during suppression than retrieval memories in GAD patients vs. HC |
| Ellard | GAD = 21, 29.48±8.44 | GAD = 21/0 | No other current psychiatric disorders | No current psychotropic drug use | 3 T fMRI Task: worry or emotion suppression | Emotion acceptance resulted in lower ratings of distress than worry and was associated with increased dorsal ACC activation and increased VLPFC-amygdala functional connectivity Worry showed greater distress ratings than acceptance or suppression and was associated with increased PCu, VLPFC, amygdala, and hippocampal activation |
| Fitzgerald | GAD = 30, 27.20±7.57 | GAD = 18/12 | GAD = 13 | No current psychotropic drug use | 3 T fMRI Task: negative emotion processing task | GAD patients exhibited over-engagement of amygdala and frontal regions during the viewing of negative images vs. HC |
| MacNamara | Patients = 142, 25.9±6.9 | HC = 40/17 | No other current psychiatric disorders | No current psychotropic drug use | 3 T fMRI Task: facial emotion processing task | Anxiety symptom scores were associated with increased anger>shape activation in bilateral insula, anterior/midcingulate, and DLPFC, while depressive symptom scores were associated with reduced DLPFC activation for Angry > Shapes across the three disorders |
| Carlson | GAD = 17, 23±4.47 | GAD = 17/0 | MDD = 15 | No current psychotropic drug use | 3 T fMRI Task: entire pilot episode of ABC's TV- series Lost | Decreased activity of amygdala in GAD and MDD patients vs. HC Higher coupling with negative valence in PCC, DMPFC, PCu in HC vs. GAD patients and MDD |
| Blair | GAD = 18, 31.0±7.78 | GAD = 8/10 | No other current psychiatric disorders | No current psychotropic drugs | 1.5 T fMRI Task: fear generalization and positive tasks | Reduced mPFC in GAD patients vs. HC and SAD patients Increased activity for low relative to high positive and negative impact events in rostral mPFC, right IFG/anterior insula, bilateral frontal cortex in GAD patients vs. HC |
| White | GAD = 46, 30.78±9.69 | GAD = 35/11 | GSAD = 18 | No current psychotropic drug use | 3 T fMRI Task: passive avoidance task |
Reduced correlation between prediction error within VMPFC, ventral striatum, dACC/DMPCF, anterior insular cortex, and PCC in GAD patients vs. HC |
| Mohlman | GAD = 20, 67.85±4.55 | GAD = 75/25% | No other current psychiatric disorders | Three participants (two in the GAD group and one in the control group) were taking medication for sleep problems. | 3 T fMRI Task: neutral and worry tasks |
Activation in frontal regions, amygdala, and insula in GAD patients vs. HC |
| Buff | GAD = 19, 28.2±8.9 | GAD = 14/5 | All patients had primary GAD with mild depression | No current psychotropic drugs | 3 T fMRI Task: disorder-related vs. neutral scripts | Increased activation in amygdala, DMPFC, VLPFC, and thalamus in GAD patients vs. HC Reduced activation in VMPFC/ subgenual ACC in GAD vs. HC |
| Rabany | GAD = 10, 41.90±5.1 | GAD = 2/8 | No other current psychiatric disorders | No current psychotropic drug use | 3 T rs-fMRI | Altered connectivity between amygdala and all regions of the default mode network and salience network in GAD patients vs. HC |
| Yin | GAD = 20, 15.7±1.7 | GAD = 15/5 | Specific phobia = 4 SP = 3 Agoraphobia = 3 PD = 2 SAD = 2 Oppositional defiant = 1 | No current psychotropic drug use | 3 T fMRI Task = emotional valence-evaluation tasks |
Evaluation of negative vs. neutral stimuli: |
| Qiao | GAD = 20, 41.5±10.7 | GAD = 13/7 | No other current psychiatric disorders | No current psychotropic drug use | 3 T rs-fMRI |
Increased functional connectivity in amygdala, insula, putamen, thalamus, and PCC in GAD patients vs. HC |
| Xia | GAD = 31, 36.87±9.16 | GAD = 16/15 | No other current psychiatric disorders | No current psychotropic drugs | 3 T rs-fMRI | Decreased ReHo values in right orbital middle frontal gyrus, left ACC, right middle frontal gyrus and supplementary motor areas as well as decreased ReHo values in left middle temporal gyrus, left superior temporal gyrus, and right superior occipital gyrus in GAD patients vs. HC |
| Buff | GAD = 19, 28.26±8.93 | GAD = 15/4 | MDD = 3 PTSD = 1 Specific phobia =1eating disorder=1 | Seven GAD patients took long-term medication | 3 T fMRI Task: fear conditioning tasks | Increased activation of amygdala and BNST during threat anticipation in GAD patients vs. HC |
| Karim | GAD = 20, 67 | GAD = 13/7 | Patients with other anxiety disorders or unipolar depression were included if GAD was the principal diagnosis, but participants with current MDD at the time of scanning were excluded. Patients with a past history of alcohol or substance abuse who were in full remission for at least 3 months were included. | No current psychotropic drug use | 3 T fMRI Task: worry induction task |
Increased activation of visual cortex, thalamus, caudate, and medial frontal cortex in GAD patients vs. HC |
| Burkhouse | GAD+SAD+ | GAD+SAD+ | No other current psychiatric disorders | No current psychotropic drug use |
3 T fMRI Task: facial emotion processing task |
Pre-treatment: Increased activation in rostral ACC when matching shapes in the context of threat distractors in the anxious group vs HC. Post-treatment (SSRI or CBT): activation in the rostral |
ACC = anterior cingulate cortex; AD = antidepressive medication; ADHD = attention deficit and hyperactivity disorder; BDZ = benzodiazepines; BLA = basolateral amygdala; BNST = bed nucleus of the stria terminalis; CaC = calcarine cortex; Cb = cerebellar cortex; CBT = cognitive-behavioral therapy; CMA = centromedial amygdala; Cun = cuneus; dACC = dorsal anterior cingulate cortex; DLPFC = dorsolateral prefrontal cortex; DMPFC = dorsomedial prefrontal cortex; EER = explicit emotion regulation; EFMT = emotion face matching task; F = female; fMRI = functional magnetic resonance imaging; FuG = fusiform gyrus; GAD = generalized anxiety disorder; GSAD = generalized social anxiety disorder; HC = healthy control; IFG = inferior frontal gyrus; LiG = lingual gyrus; M = male; MBSR = mindfulness based stress reduction; MDD = major depressive disorder; MPFC = medial prefrontal cortex; MRI = magnetic resonance imaging; n = patients; OCD = obsessive-compulsive disorder; PCC = posterior cingulate cortex; PCu = precuneus; PD = panic disorder; PFC = prefrontal cortex; pgACC = pregenual anterior cingulate cortex; PHG = parahippocampal gyrus; PLC = placebo; PTSD = posttraumatic stress disorder; ReHo= regional homogeneity; rs-fMRI = resting-state fMRI; SAD = separation anxiety disorder; SD = standard deviation; SFG = superior frontal gyrus; SME = stress management education; SMG = supramarginal gyrus; SOG = superior occipital gyrus; SP = social phobia; SPG = superior parietal gyrus; SSRI = selective serotonin reuptake inhibitors; STG = superior temporal gyrus; STIMEX = stimulus expectancy task; TAC = top-down attentional control; VLPFC = ventrolateral prefrontal cortex; VMPFC = ventromedial prefrontal cortex; vPFC = ventral prefrontal cortex; VTA = ventral tegmental area.
In this study patients with different diagnoses were considered as a whole group.
Figure 2Brain regions consistently found to be involved in generalized anxiety disorder from structural and functional MRI studies.